Abstracts Archive - Page 616 of 2425 - ACR Meeting Abstracts

Abstract Number: 1878 • ACR Convergence 2021
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Diana Prieto-Peña¹, Pilar Bernabeu², Paloma Vela³, Javier Narvaez⁴, Jesús Carlos Fernández-López⁵, Mercedes Freire⁶, Beatriz González-Alvarez⁷, Roser Solans-Laqué⁸, José Luis Callejas⁹, Norberto Ortego¹⁰, Carlos Fernández-Díaz¹¹, Esteban Rubio Romero¹², Salvador Garcia-Morillo¹³, Mauricio Minguez¹⁴, Cristina Carballido¹⁴, Eugenio De Miguel¹⁵, Sheila Melchor¹⁶, Eva Salgado¹⁷, Beatriz Bravo¹⁸, Susana Romero-Yuste¹⁹, Juan Salvatierra²⁰, Cristina Hidalgo²¹, Sara Manrique Arija²², Carlos Romero Gomez²³, Patricia Moya²⁴, Noelia Álvarez-Rivas²⁵, Javier Mendizábal-Mateos²⁶, Francisco Ortiz-Sanjuán²⁷, Ivan Perez De Pedro²⁸, Jose L Alonso-Valdivielso²⁹, Laura Perez-Sanchez³⁰, Rosa Roldan³¹, Nagore Fernandez-Llanio³², Ricardo Gómez de la Torre³³, Silvia Suarez³³, Mara Jess Montesa Cabrera³⁴, MONICA DELGADO SANCHEZ³⁵, Javier Loricera¹, Belén Atienza-Mateo³⁶, Miguel Ángel gonzalez-Gay³⁷ and Ricardo Blanco³⁸, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ³Hospital General Universitario de Alicante, Alicante, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ⁶Rheumatology Service. CHU Coruña, La Coruña, Spain, ⁷H. NªSª de la Candelaria, Tenerife, Spain, ⁸Hospital Vall d'Hebron, Barcelona, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Medicine Department, Universidad de Granada, Granada, Spain, ¹¹Hospital Universitario Reina Sofía, Murcia, Spain, ¹²HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, Seville, Spain, ¹³H Virgen del Rocio, Sevilla, Spain, ¹⁴H. San Juan, Alicante, Spain, ¹⁵Hospital Universitario La Paz, Madrid, Spain, ¹⁶H. 12 de Octubre, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ²⁰H San Juan, Alicante, Spain, ²¹Hospital Universitario Salamanca, Salamanca, Spain, ²²Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ²³H. Regional de Malaga, Malaga, Spain, ²⁴Hospital Sant Pau, Barcelona, Spain, ²⁵Hospital San Agustín, Aviles, Spain, ²⁶H. Navarra, Navarra, Spain, ²⁷H. La Fe, Valencia, Spain, ²⁸H. Carlos Haya, Malaga, Spain, ²⁹H. Burgos, Burgos, Spain, ³⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³¹H. Reina Sofia, Cordoba, Spain, ³²H. Arnau de Vilanova, Valencia, Spain, ³³H. Asturias, Oviedo, Spain, ³⁴Hospital Universitario Nuestra Seora de la Candelaria, Santa Cruz de Tenerife, Spain, ³⁵H NªSª Candelaria, Tenerife, Spain, ³⁶Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients.…
Abstract Number: 1881 • ACR Convergence 2021
Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease
Youjin Jung and Eun bong Lee, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Behcet's disease (BD) is characterized by hyper-inflammatory response to trauma, which is called the pathergy phenomenon. Therefore, there are concerns about post-operative complications when…
Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Elisheva Pokroy-Shapira¹, Iftach Sagy², Katya Meridor³ and Yair Molad⁴, ¹Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, ²Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ³Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ⁴Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Alba Herrero-Morant¹, José Luis Martin-Varillas², Vanesa Calvo-Río³, Santos Castañeda⁴, Olga Maíz⁵, Ana Blanco⁶, Julio Sánchez⁷, Norberto Ortego⁸, Enrique Raya⁹, Anahy Maria Brandy-Garcia¹⁰, Alejandro Olive-Marques¹¹, Agueda Prior-Español¹², Clara Moriano¹³, Elvira Díez¹⁴, Rafael Melero¹⁵, Jenaro Enrique Grana Gil¹⁶, Álvaro Seijas-López¹⁷, Ana Urruticoechea-Arana¹⁸, Ángel Ramos-Calvo¹⁹, Concepcion Delgado-Beltran²⁰, Marta Loredo-Martinez²⁰, Eva Salgado²¹, Francisca Sivera²², Ignacio Torre²³, Javier Narvaez²⁴, Jose Luis Andreu²⁵, Olga Martinez²⁶, Ricardo Gómez de la Torre²⁷, Sabela Fernandez-Aguado²⁸, Susana Romero-Yuste²⁹, Gerard Espinosa³⁰, Miguel Ángel gonzalez-Gay³¹ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Hospital Universitario de Donostia, San Sebastián, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Medicine Department, Universidad de Granada, Granada, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Rheumatology Service. Hospital Germans Trias i Pujol, Barcelona, Spain, ¹²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ¹³Hospital Universitario de León, León, Spain, ¹⁴Hospital de León, León, Spain, ¹⁵Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁶Hospital Universitario de A Coruña, A Corua, Spain, ¹⁷Hospital Universitario de A Coruña, A Coruña, Spain, ¹⁸H. Can Misses, Elvissa, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰Hospital Clínico Lozano Blesa, Zaragoza, Spain, ²¹Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²²Hospital Universitario de Elda, Alicante, Spain, ²³Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶H. Salamanca, Zamora, Spain, ²⁷H. Asturias, Oviedo, Spain, ²⁸Hospital Universitario de Cabueñes, Gijón, Spain, ²⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…
Abstract Number: 1887 • ACR Convergence 2021
Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Maria Caterina Lagdameo¹, Hyungrok Do² and Johannes Nowatzky¹, ¹Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Population Health, NYU School of Medicine, New York
Background/Purpose: Most current Behçet’s disease (BD) activity assessment tools are strongly based on patient-reported symptoms and findings allowing a wide range of observer-dependent interpretations and…
Abstract Number: 1886 • ACR Convergence 2021
Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis
K. Bates Gribbons¹, SEMA KAYMAZ-TAHRA², Fatma Alibaz³, Ertugrul Cagri bolek⁴, Omer Karadag⁵, Burak Ince⁶, Murat Inanc⁷, Sinem Kocaer⁸, Fatos Onen⁹, KENAN AKSU¹⁰, Gokhan Keser¹¹, Askin Ates¹², Ayten Yazici¹³, Ayse Cefle¹³, Nilufer Alpay Kanitez¹⁴, Ahmet Omma¹⁵, Onay Gercik¹⁶, Servet Akar¹⁷, Veli Cobankara¹⁸, Nazife Sule Yasar Bilge¹⁹, Timucin Kasifoglu²⁰, Mete Kara¹¹, Kaitlin Quinn²¹, Peter Grayson²², Peter Merkel²³ and Haner Direskeneli²⁴, ¹McGovern Medical School, Colleyville, TX, ²Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ⁸Dokuz Eylul University, Izmer, Turkey, ⁹Dokuz Eylul University, Izmir, Turkey, ¹⁰EGE UNIV. FACULTY of MEDICINE, IZMIR, Turkey, ¹¹Ege University, İzmir, Turkey, ¹²Ankara University, Ankara, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Koc University School of Medicine, Istanbul, Turkey, ¹⁵Ankara City Hospital, Istanbul, Turkey, ¹⁶Izmir Katip Celebi University, Izmir, Turkey, ¹⁷Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹⁸Pamukkale University, Denizli, Turkey, ¹⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ²⁰Osmangazi University Department of Rheumatology, Eskişehir, Turkey, ²¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Marmara University, Istanbul, Turkey
Background/Purpose: Previous studies using computer-driven methods have identified subsets of patients with Takayasu’s arteritis based on angiographic patterns of disease. These subsets were consistent between…
Abstract Number: 1889 • ACR Convergence 2021
Arthritogenic T Cells Harbor a Transcriptional Program of T Cell Activation and a Repertoire Pruned by Endogenous Superantigen
JUDITH F ASHOURI, Elizabeth McCarthy, Steven Yu, Noah Perlmutter, Charles Lin, Chun Jimmie Yu and Arthur Weiss, University of California San Francisco, San Francisco, CA
Background/Purpose: It is widely accepted that activation of specific CD4 T cells through their TCRs by self-antigen (Ag) is necessary for rheumatoid arthritis (RA) onset.…
Abstract Number: 1891 • ACR Convergence 2021
Variable Effects of Testosterone on Male versus Female Derived Macrophages in Inflammatory Arthritis
Kiana Chen¹, Xi Lin¹, Lianping Xing², H. Mark Kenney³, Richard Bell⁴, Edward Schwarz⁵ and Homaira Rahimi⁵, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester Medical Center, Webster, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that is female predominant. The TNF-transgenic (TNF-Tg) mouse model of RA also develops a sexually…
Abstract Number: 1892 • ACR Convergence 2021
Promotion of Autoimmune Arthritis via Tryptophan Metabolism and Production of the Bacterial-Derived Tryptophan Metabolite Indole
Brandon Trent¹, Meagan Chriswell², Widian Jubair¹ and Kristine Kuhn¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²UC Denver SOM, Denver, CO
Background/Purpose: Significant changes in gut bacterial richness and diversity occur during the development of inflammatory arthritis, in both murine models and human patients; however, the…
Abstract Number: 1888 • ACR Convergence 2021
Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD
Gözde Kübra Yardımcı¹, Bayram Farisogulları², Gizem Ayan¹, Levent Kilic¹, Sule Apraş Bilgen¹ and Omer Karadag³, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, ³Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…
Abstract Number: 1849 • ACR Convergence 2021
False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center
Brian Lam¹, Rana Taherian¹, Julio Charles¹, Maureen Mayes², Shervin Assassi³ and Brian Skaug⁴, ¹Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴University of Texas McGovern Medical School Houston, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a progressive autoimmune disease with high morbidity and mortality, making early diagnosis and management critical. Anti-Topoisomerase I antibody (anti-Topo I,…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 1896 • ACR Convergence 2021
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Anna Montgomery¹, Gary Tarasovsky², Iziegbe Ehiorobo³, Mary Whooley², Jennifer Barton⁴, Khushboo Sheth⁵, Kimberly Reiter⁶, Meredith Keller⁷, Lorinda Chung⁸, Lori Bennett⁹, Jo Dana², Elizabeth Wahl¹⁰ and Gabriela Schmajuk³, ¹Department of Veterans Affairs, Tiburon, CA, ²San Francisco VA Healthcare System, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴Portland VA Healthcare System, Portland, OR, ⁵Stanford University/VA Palo Alto, Atherton, CA, ⁶Raymond G Murphy VA Medical Center, Albuquerque, NM, ⁷New Mexico VA Health Care System, Albuquerque, NM, ⁸Stanford University, Palo Alto, CA, ⁹Charleston VAHCS, Charleston, SC, ¹⁰VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for patients with lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. However, HCQ daily doses of ≥…
Abstract Number: 1894 • ACR Convergence 2021
Natural Language Processing Tool for Extraction of Patient-Reported Outcomes from a National Multi-Electronic Health Records Registry
Marie Humbert-Droz¹, Zara Izadi², Gabriela Schmajuk², Milena Gianfrancesco², Jinoos Yazdany² and Suzanne Tamang³, ¹Stanford University, Stanford, ²University of California San Francisco, San Francisco, CA, ³Stanford Center for Population Health Sciences, Redwood City, CA
Background/Purpose: Patient reported outcomes (PROs) are increasingly used to track disease activity and facilitate shared decision making in patients with RA. Assessments of disease activity…
Abstract Number: 1900 • ACR Convergence 2021
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
James O'Dell¹, Tuhina Neogi², Michael Pillinger³, Paul Palevsky⁴, Jeff Newcomb¹, Mary Brophy⁵, Hongsheng Wu⁵, Annie Davis-Karim⁶, Ryan Ferguson⁵, David Pittman⁶, Robert Terkeltaub⁷, Amy Cannella¹, Bryant England¹, Lindsay Helget¹, Ted Mikuls¹ and Tomas Taylor⁸, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³New York University Grossman School of Medicine, New York,, NY, ⁴Pittsburgh University, Pittsburgh, PA, ⁵Boston VA, Boston, MA, ⁶Albuquerque VA, Albuquerque, NM, ⁷VA/UCSD, San Diego, CA, ⁸White River Junction VA, White River Junction, VT
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].